Published in Curr Mol Med on July 01, 2001
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis (2009) 1.29
Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front Aging Neurosci (2010) 0.98
Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol (2010) 0.96
Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol (2008) 0.92
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol (2014) 0.79
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol (2015) 0.78
Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells. Sci Rep (2015) 0.78
Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease. PLoS One (2013) 0.77
Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan. PLoS One (2015) 0.77
In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM. World J Gastroenterol (2015) 0.76
Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol (2005) 0.76
Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. J Ophthalmol (2010) 0.76
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases. Diagnostics (Basel) (2016) 0.75
Protein modification by dicarbonyl molecular species in neurodegenerative diseases. J Amino Acids (2011) 0.75
Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A (1992) 2.09
Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A (1993) 2.00
Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med (1991) 1.78
Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A (1994) 1.78
Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol (1993) 1.60
Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med (1991) 1.59
Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol (1998) 1.49
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med (2000) 1.42
Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res (2001) 1.31
Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes (1995) 1.25
Sequencing of the putative promoter region of the cocaine- and amphetamine-regulated-transcript gene and identification of polymorphic sites associated with obesity. Int J Obes Relat Metab Disord (2002) 1.19
Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia (1999) 1.13
Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol (2000) 1.09
Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes (1997) 1.05
Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol Med (1999) 1.01
Neurotoxicity of methylglyoxal and 3-deoxyglucosone on cultured cortical neurons: synergism between glycation and oxidative stress, possibly involved in neurodegenerative diseases. J Neurosci Res (1999) 1.00
Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol (1997) 0.97
Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism (1998) 0.95
Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy. Hum Pathol (1995) 0.94
Immunological detection of a novel advanced glycation end-product. Mol Med (2001) 0.92
Radioreceptor assay for advanced glycosylation end products. Diabetes (1991) 0.91
Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med (1993) 0.91
Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm Metab Res (2001) 0.88
Involvement of pRB-related p107 protein in the inhibition of S phase progression in response to genotoxic stress. J Biol Chem (2001) 0.87
Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm Metab Res (2002) 0.84
Radioimmunoassay for non-enzymatically glycated serum proteins. Horm Metab Res (1989) 0.83
Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res (2002) 0.81
Advanced glycosylation end products in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis (1993) 0.79
Enhancement of oxidised low-density lipoprotein uptake by macrophages in response to macrophage migration inhibitory factor. Cytokine (2000) 0.78
Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract (1997) 0.77
Insulin response patterns contribute to different perinatal risks in gestational diabetes. Gynecol Obstet Invest (2001) 0.77
Quantitative enzyme-linked immunosorbent assay (ELISA) for non-enzymatically glycated serum protein. J Immunol Methods (1987) 0.76
[Case of probable Wernicke's encephalopathy following administration of a massive dosage of furosemide]. Nihon Naika Gakkai Zasshi (1983) 0.75
A radioimmunoassay for an advanced glycosylation endproduct. J Immunol Methods (1988) 0.75
[Advanced glycation endproduct (AGE)]. Nihon Rinsho (1998) 0.75
[Diagnosis, treatment, and management of diabetic complications. 4. Nephropathies]. Nihon Naika Gakkai Zasshi (2000) 0.75
[The role of AGE and AGE-inhibition in the pathogenesis of diabetic glomerulosclerosis]. Nihon Ronen Igakkai Zasshi (2000) 0.75
[A methodological study on the solid phase radioimmunoassay of serum insulin]. Horumon To Rinsho (1982) 0.75
Advanced glycation end products and the pathogenesis of diabetic nephropathy. Contrib Nephrol (2001) 0.75
[Advanced glycation endproduct (AGE)]. Nihon Rinsho (1998) 0.75